The American Society for Radiation Oncology (ASTRO) seeks to recognize an individual cancer survivor in the San Francisco Bay area who has dedicated his or her time and energy to helping their local community.
Dose-escalated intensity modulated radiation therapy (IMRT) with use of a moderate hypofractionation regimen (72 Gy in 2.4 Gy fractions) can safely treat patients with localized prostate cancer with limited grade 2 or 3 late toxicity, according to a study published in the April 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).
The American Society for Radiation Oncology (ASTRO) has issued a new white paper, “A review of safety, quality management, and practice guidelines for high-dose-rate brachytherapy,” that recommends specific guidance to follow in the delivery of high-dose-rate (HDR) brachytherapy to improve quality and patient safety, according to the manuscript published in the March-April 2014 print issue of Practical Radiation Oncology (PRO), the official clinical practice journal of ASTRO.
Patients who received daily humidification of the mouth and throat region beginning from day one of radiation therapy treatment spent nearly 50 percent fewer days in the hospital to manage their side effects, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.
A retrospective analysis of oropharyngeal patients with recurrence of disease after primary therapy in the Radiation Therapy Oncology Group (RTOG) studies 0129 or 0522 found that HPV-positive patients had a higher overall survival (OS) rate than HPV-negative patients (at two years post-treatment, 54.6 percent vs. 27.6 percent, respectively), according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.
Evaluating next-generation sequencing (NGS) data and associated clinical records of head and neck squamous cell carcinoma (HNSCC) patients from several institutions, made available through The Cancer Genome Atlas (TCGA), showed that combining Mutant-Allele Tumor Heterogeneity (MATH) as a biomarker with the patient’s HPV status provides an effective indicator of improved patient outcome, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.
Patients with HPV-positive squamous cell carcinoma of the oropharynx (SCCOP) had a longer time to development of distant metastasis (DM) after initial treatment, and had more metastatic sites in more atypical locations compared to HPV-negative patients, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.
Avoiding the contralateral submandibular gland during radiation therapy is feasible and safe with advanced stage, node positive head and neck cancers and base of tongue lesions, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.
Oropharyngeal cancer patients treated with combined chemotherapy and radiation therapy reported a decrease in their voice and speech quality (VSQ) for up to one year after the completion of treatment, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.
For head and neck cancer patients undergoing radiation therapy, a reduction in the amount of radiation treatment volume to the submandibular (level IB) lymph nodes resulted in better patient-reported salivary function, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.
Limiting radiation therapy to lymph nodes on one side of the neck for advanced tonsil cancer resulted in good local regional control and no cancer recurrence on the untreated side, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.
The American Society for Radiation Oncology (ASTRO) and the Society of Surgical Oncology (SSO) are pleased to announce the publication of the consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer.
Standard external beam radiation therapy (EBRT) provided a higher breast preservation rate than brachytherapy in women age 66 and older with invasive breast cancer, according to a study published in the February 1, 2014 print edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).
Long-term (five-year) outcomes of breast cancer patients receiving adjuvant accelerated partial breast irradiation (APBI) after breast-conserving surgery show excellent tumor control and breast cosmesis (cosmetic outcomes) with minimal late toxicity, according to a study published in the February 1, 2014 print edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).
The Radiation Oncology Institute (ROI) has selected Christopher G. Slatore, MD, an assistant professor in the division of pulmonary and critical care medicine at the Portland VA Medical Center in Portland, Oregon, and a leader in patient-centered lung cancer research, to receive a $200,000 award, distributed over two years, for a project to examine the comparative value of radiation therapy and patient outcomes among lung cancer patients.
The Radiation Oncology Institute (ROI) has selected Malolan S. Rajagopalan, MD, a radiation oncology resident at the University of Pittsburgh Cancer Institute, to receive a $20,000 grant for a project to compile best practices regarding the management of radiation therapy toxicity.
The 2014 Multidisciplinary Head and Neck Cancer Symposium, sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO) and the American Head & Neck Society (AHNS), will explore the heterogeneous group of tumors in head and neck cancers, and the various complexities and factors in providing treatment.
The American Society for Radiation Oncology (ASTRO) has released a new report, “Current Status and Recommendations for the Future of Research, Teaching and Testing in the Biological Sciences of Radiation Oncology: Report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force.”
A comprehensive review of Medicare claims for more than 45,000 patients from 2005 through 2010 found that nearly all of the 146 percent increase in intensity- modulated radiation therapy (IMRT) for prostate cancer among urologists with an ownership interest in the treatment was due to self-referral, according to new research, “Urologists’ Use of Intensity- Modulated Radiation Therapy for Prostate Cancer,” released today in The New England Journal of Medicine (NEJM) for its October 24, 2013 issue.
Standard and reduced high-dose volume radiation therapy for muscle-invasive bladder cancer provide comparable tumor control and decreased late toxicity when compared to surgery, according to a study published in the October 1, 2013 print edition of the International Journal of Radiation Oncology ● Biology ● Physics, the official scientific journal of the American Society for Radiation Oncology (ASTRO).
Detailed evaluation of a prostate cancer tumor biopsy may predict treatment outcomes for image-guided radiation therapy (IGRT) or surgery for prostate cancer, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 55th Annual Meeting.
The American Society for Radiation Oncology (ASTRO) has elected four new officers to serve on its Board of Directors. The new officers’ terms for 2013-14 will begin at the Annual Business Meeting on Tuesday, September 24, 2013, at 11:30 a.m. Eastern time, at ASTRO’s 55th Annual Meeting in Atlanta, September 22-25, 2013.
Early-stage breast cancer patients who receive external beam therapy (XRT) are not at higher risk for serious long-term side effects in the chest area, including increase in deaths from cardiac disease and secondary malignancies, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 55th Annual Meeting.
A secondary analysis of the historic RTOG 9202 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy, and concluded that there were no additional benefits when compared to short-term hormonal therapy, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 55th Annual Meeting.
An analysis of quality of life (QOL) data of stage III lung cancer patients who received higher doses of radiation therapy (with chemotherapy) shows a significantly lower quality of life at 3 months after treatment compared to patients who received a standard dose of radiation (with chemotherapy), according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 55th Annual Meeting.
Limiting the amount of radiation absorbed in the hippocampal portion of the brain during whole-brain radiotherapy (WBRT) for brain metastases preserves memory function in patients for up to six months after treatment, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 55th Annual Meeting.
A shorter course of androgen suppression therapy prior to radiation therapy, when compared to a longer course of androgen suppression therapy, yields favorable outcomes and fewer adverse effects for intermediate-risk prostate cancer patients, according to research presented today at the American Society for Radiation Oncology’s (ASTRO) 55th Annual Meeting.
Cancer patients receiving radiotherapy (RT) who are potentially suffering from depression can be effectively identified by a two-item questionnaire, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 55th Annual Meeting.
The American Society for Radiation Oncology (ASTRO) will highlight the recently published Adjuvant and Salvage Radiotherapy After Prostatectomy: ASTRO/AUA Guideline during ASTRO’s 55th Annual Meeting, September 22-25, 2013, in Atlanta.
When treated with stereotactic radiosurgery (SRS), that is not combined with whole brain radiotherapy (WBRT), adult brain cancer patients who were 50 years old and younger were found to have improved survival, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 55th Annual Meeting.
Proton therapy, an external beam radiotherapy in which protons deliver precise radiation doses to a tumor and spare healthy organs and tissues, is cost-effective in treating medulloblastomas, fast-growing brain tumors that mainly affect children, when compared to standard photon radiation therapy, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 55th Annual Meeting.
Adding the chemotherapy drug cisplatin to a treatment plan of radiation therapy (RT) and high-dose-rate brachytherapy (HDRB) for stage IIIB cervical cancer is beneficial, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 55th Annual Meeting. The study also indicated that the combined treatments produced acceptable levels of toxicity.
Sulfasalazine does not reduce diarrhea, according to research presented today at the American Society of Radiation Oncology’s (ASTRO’s) 55th Annual Meeting. The study also determined that the medication may be associated with a higher risk of diarrhea than placebo.
When used to treat pediatric patients with intracranial malignant tumors, proton therapy may limit the toxicity of radiation therapy while preserving tumor control, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 55th Annual Meeting.
The American Society for Radiation Oncology (ASTRO) has selected two Georgia cancer patient support groups, The Cancer Foundation of Northeast Georgia and the South Georgia Medical Center, Pearlman Cancer Center, to receive ASTRO’s 2013 Survivor Circle grants.
The American Society for Radiation Oncology (ASTRO) has selected Atlanta resident and cancer survivor Sherri Graves Smith to receive the 2013 Survivor Circle Award.
The American Society for Radiation Oncology (ASTRO) has selected health care researcher Jean B. Owen, PhD, as the 2013 Honorary Member, the highest honor ASTRO bestows on distinguished cancer researchers, scientists and leaders in disciplines other than radiation oncology, radiobiology and radiation physics.
The American Society for Radiation Oncology (ASTRO) praises the “Delivering High-Quality Cancer Care: Charting a News Course for a System in Crisis” report, issued earlier today by the Institute of Medicine (IOM) of the National Academies.
The Association for Residents in Radiation Oncology (ARRO) has recognized 56 educators with the 2013 ARRO Educator of the Year Award.
ASTRO’s 55th Annual Meeting
The American Society for Radiation Oncology (ASTRO) has selected 10 distinguished members to receive the Fellow of ASTRO designation (FASTRO). The 2013 class of Fellows will receive the recognition during the Awards Ceremony on Tuesday, September 24, at ASTRO’s 55th Annual Meeting, September 22-25, 2013, at the Georgia World Congress Center in Atlanta.
The American Society for Radiation Oncology (ASTRO) has selected 42 recipients for the 2013 Annual Meeting Abstract Awards. The awardees will receive a total of $34,500 and be honored at ASTRO’s 55th Annual Meeting, September 22-25, 2013, at the Georgia World Congress Center in Atlanta.
The American Society for Radiation Oncology (ASTRO) has selected seven (7) leading researchers who will receive a total of $675,000 in awards and grants to advance radiation oncology research.
ASTRO Chairman Michael L. Steinberg, MD, FASTRO, called attention to the Government Accountability Office’s (GAO) striking report released today, “Medicare: Higher Use of Costly Prostate Cancer Treatment by Providers Who Self-Refer Warrants Scrutiny,” that details clear mistreatment of patients who trusted their physicians to care for their prostate cancer.
Michael L. Steinberg, MD, FASTRO, chairman of the American Society for Radiation Oncology’s (ASTRO) Board of Directors, states that Dr. Jacobs, et.al.’s study reaffirms the Society’s commitment to closing the self-referral loophole for radiation therapy within the Ethics in Patient Referrals Act, also known as the self-referral law.
The American Society for Radiation Oncology (ASTRO) will award Amato J. Giaccia, PhD, Radhe Mohan, PhD, FASTRO, and Prabhakar Tripuraneni, MD, FASTRO, with the Society’s highest honor—the ASTRO Gold Medal. The 2013 awardees will receive the ASTRO Gold Medal during the Awards Ceremony on Tuesday, September 24, at ASTRO’s 55th Annual Meeting, September 22-25, 2013, at the Georgia World Congress Center in Atlanta.
Radiation oncology research received 197 grants, totaling only 1.6 percent ($85.5 million) of the $5.4 billion in cancer research funding from the National Institutes of Health (NIH) in Fiscal Year (FY) 2013, according to a study available online and in the June 1, 2013, print issue of the International Journal of Radiation Oncology • Biology • Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).
The Radiation Oncology Institute (ROI) is seeking proposals to examine the comparative value of radiation therapy and will provide support for the research project in the amount of $200,000 over two years. A Letter of Intent is due to ROI by Friday, June 21, 2013, with the full project proposal due on Friday, September 20, 2013. Detailed information about the Request for Proposal (RFP) and the grant application process is available at www.roinstitute.org.
ASTRO’s Annual Meeting is the premier scientific meeting in radiation oncology and is expected to attract more than 11,000 attendees including oncologists from all disciplines, medical physicists, dosimetrists, radiation therapists, radiation oncology nurses and nurse practitioners, biologists, physician assistants, practice administrators, industry representatives and other health care professionals from around the world.
The American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA) are pleased to announce the publication of the joint guideline on radiation therapy after prostatectomy for patients with and without evidence of prostate cancer recurrence.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right